1. Home
  2. CBUS vs BDSX Comparison

CBUS vs BDSX Comparison

Compare CBUS & BDSX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cibus Inc.

CBUS

Cibus Inc.

HOLD

Current Price

$1.67

Market Cap

142.7M

Sector

Industrials

ML Signal

HOLD

Logo Biodesix Inc.

BDSX

Biodesix Inc.

HOLD

Current Price

$27.45

Market Cap

153.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CBUS
BDSX
Founded
2010
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Agricultural Chemicals
Precision Instruments
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
142.7M
153.3M
IPO Year
2017
2020

Fundamental Metrics

Financial Performance
Metric
CBUS
BDSX
Price
$1.67
$27.45
Analyst Decision
Buy
Strong Buy
Analyst Count
2
5
Target Price
$9.00
$32.50
AVG Volume (30 Days)
138.8K
119.9K
Earning Date
05-14-2026
05-04-2026
Dividend Yield
N/A
N/A
EPS Growth
74.33
N/A
EPS
N/A
N/A
Revenue
$3,639,000.00
$88,499,000.00
Revenue This Year
$112.72
$25.26
Revenue Next Year
$83.18
$19.15
P/E Ratio
N/A
N/A
Revenue Growth
N/A
24.08
52 Week Low
$1.09
$0.35
52 Week High
$4.19
$31.31

Technical Indicators

Market Signals
Indicator
CBUS
BDSX
Relative Strength Index (RSI) 42.52 59.35
Support Level $1.55 $19.26
Resistance Level $1.82 N/A
Average True Range (ATR) 0.12 2.42
MACD -0.02 0.37
Stochastic Oscillator 23.85 60.53

Price Performance

Historical Comparison
CBUS
BDSX

About CBUS Cibus Inc.

Cibus Inc is a biotechnology company. The company develops and commercializes a proprietary gene-editing technology, Rapid Trait Development System that integrates crop specific cell biology platforms with a series of gene editing technologies. The company's primary business is the development of plant traits that help address specific productivity or yield challenges in farming such as traits addressing plant agronomy, disease, insects, weeds, nutrient-use, or the climate.

About BDSX Biodesix Inc.

Biodesix Inc is a diagnostic solutions company with a focus on lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources: providing diagnostic testing services associated with blood-based lung and COVID tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties, as well as the development and commercialization of companion diagnostics.

Share on Social Networks: